Home  |  Corporate Info  |  R & D  |  Products  |  Investor Relations  |  For the Patient  |  Careers at Hemispherx  


For the Patient
Educational Resources
Clinical Trial Information
Professional Services



 

AMP 516

 

A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Poly I: Poly C12U (Ampligen®) 400 MG IV Twice Weekly Versus Placebo in Patients with Severely Debilitating Chronic Fatigue Syndrome (CFS)/ Myalgic Encephalomyelitis (ME).

Design: Mission Data?

Eligibility:
Subjects who meet the following criteria may be eligible for study participation.

Status:
The study is open to enrollment.

Locations:
Eleven centers in the US are currently participating in this study.  Cities with participating centers are:

  • Fountain Valley, CA

  • San Diego, CA

  • Manchester, CT

  • Hollywood, FL

  • Chicago, IL

  • Charlotte, NC

  • New Brunswick, NJ

  • New Providence, NJ

  • Incline Village, NV

  • Glenn Mills, PA

  • Middleton, WI

Please contact Hemispherx Biopharma for additional information regarding trial locations and site contacts:

Phone: 215-988-0080
Fax:     215-988-1739
E-Mail: trialinfo@hemispherx.net 
 

 

 

Information contained on the Hemispherx website other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risks of competition, changing market conditions, changes in laws and regulations affecting these industries and numerous other factors discussed on the Hemispherx website and in the Company's filings with the Securities and Exchange Commission. Accordingly, actual results may differ materially from those in any forward-looking statements. Additionally, all the referenced investigational drugs and associated technologies of the company are experimental in nature and as such are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. The forward-looking statements represent the Company's judgement as of the date of this website. The Company disclaims, however, any intent or obligation to update these forward-looking statements.